Sort
48,018 grants matching “immunotherapy”
Project 1 - Characterize the Mechanism by Which Papillomaviruses Evade Host Immunity
$426,371Paul F Lambert · University Of Wisconsin-Madison · P01 · FY2024 · CA
Project 1 - Characterize the Mechanism by Which Papillomaviruses Evade Host Immunity
$426,371Paul F Lambert · University Of Wisconsin-Madison · P01 · FY2025 · CA
GENE TRANSFER and SOMATIC CELL ENGINEERING
$426,348Michel Sadelain · Sloan-Kettering Inst Can Research · P30 · FY2010 · CA
Eastern Cooperative Oncology Group
$426,296Vanderbilt University · U10 · FY2005 · CA
Immune cell control of ovarian cancer
$426,291Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Targeting TERT in Melanoma
$426,277Jessie Villanueva · Wistar Institute · R01 · FY2019 · CA
Dual-pronged nano-drug delivery using plant virus-like particles.
$426,217Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2021 · CA
Pathology Core
$426,198Xiaowei Xu · Wistar Institute · P01 · FY2021 · CA
Immunobiology of Myeloid and Lymphoid Cells
$426,178Charles L Sentman · Dartmouth College · T32 · FY2019 · AI
The Role of Schwann Cells in the Progression of Melanoma
$426,170Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
INVESTIGATING ASCL1-DRIVEN IMMUNOLOGICAL LANDSCAPES IN NEUROENDOCRINE PROSTATE CANCER: A STRATEGY FOR ENHANCING IMMUNOTHERAPY EFFICACY
$426,154The University Of British Columbia · · FY2025 · Defense Health Agency
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
$426,075Zelig Eshhar · Tel-Aviv Sourasky Medical Center · R01 · FY2014 · EB
Mechanistic Study of Peanut-specific T cells Pre and Post Oral Immunotherapy
$426,052William W. Kwok · Benaroya Research Inst At Virginia Mason · R56 · FY2014 · AI
Beta-Amyloid Immunization in a Canine Model of Aging
$425,959Elizabeth Head · University Of Kentucky · R01 · FY2012 · AG
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers
$425,907Louis D Falo · University Of Pittsburgh At Pittsburgh · P50 · FY2017 · CA
Role of Toll-like Receptor 9 in Fibroblastic Reticular Cell-based Therapy for Intra-abdominal Sepsis
$425,886Meihong Deng · Feinstein Institute For Medical Research · R01 · FY2024 · AI
ROLES AND MECHANISMS OF TERTIARY LYMPHOID STRUCTURES IN ANTI-TUMOR IMMUNITY
$425,880Andrew Gunderson · Ohio State University · R01 · FY2025 · CA
Biomaterial Cancer Vaccines that Generate Patient-Specific Antigen In Situ
$425,863David J Mooney · Harvard University · R01 · FY2021 · CA
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning
$425,843Edgar G. Engleman · Stanford University · P01 · FY2019 · HL
Molecular and Cellular Mechanisms of Tolerance to Combined Organ and Hematopoietic Cell Transplantation after TLI and ATS/ATG Conditioning
$425,843Edgar G. Engleman · Stanford University · P01 · FY2020 · HL
Clinical Fellowship Training Program
$425,833Peter Pinto · Division Of Basic Sciences - Nci · ZIE · FY2010 · CA
Functional interplay between Hippo and estrogen receptor ESR1
$425,711Jing Yang · University Of California, San Diego · R01 · FY2023 · CA
Role of ALK4 in Regulating Receptor Trafficking and Pancreatic Cancer Biology
$425,689Gerard C Blobe · Duke University · R01 · FY2022 · CA
SEQUENCE, SHAPE AND SPECIFICITY OF ANTIBODIES
$425,626Massachusetts General Hospital · R01 · FY2000 · CA
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
$425,597Alexander H. Stegh · Washington University · R01 · FY2023 · CA